{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"podcast":5,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06040099\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"EMERALD-Y90","nct_id":"NCT06040099","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=emerald-y90-nct06040099. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"EMERALD-Y90","arms":[{"description":"Participants will undergo Yttrium 90 glass microspheres TARE according to the dosimetry recommendation.","label":"Yttrium 90 glass microspheres TARE in combination with Durvalumab and Bevacizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05-27","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":{"count":58,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"},{"name":"Transarterial Radioembolization (TARE)","type":"PROCEDURE"}],"last_update":"2026-09-21","lead_sponsor":"AstraZeneca","official_title":"Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-06-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From Day 1 until date of progressive disease or death [Approximately 3 years]"}],"references":[{"citation":"Pabon CM, Kumar-Sharma P, Spieler BO, Tuerff D, Datta J, Hosein PJ. Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy. Surg Oncol Clin N Am. 2026 Apr;35(2):347-365. doi: 10.1016/j.soc.2025.10.008. Epub 2026 Jan 14.","pmid":"41903993","type":"DERIVED"}],"start_date":{"date":"2024-02-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE","url":"https://clinicaltrials.gov/study/NCT06040099"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/emerald-y90-nct06040099"}